Our Mission

Alleviate the symptoms of type 2 diabetes for patients worldwide with a pioneering, reversible implant.

Product Overview
EndoBarrier treatment for diabetes & obesity

Proven Results for Type 2 Diabetes & Obesity

In two separate studies, 80% of patients maintained their achieved weight loss eight months’ post-EndoBarrier removal and 77% maintained it for 12 months or more.

BBC News Video
Endobarrier treatment for diabetes & obesity following 1 year results of ABCD study

Pioneering and Simply Effective.

EndoBarrier is the first Type 2 Diabetes and Obesity treatment of its kind: safe and reversible, with proven benefits and no surgery.

ABCD EndoBarrier Study
1-year results, including 10-year CV Risk assessment – Robert Ryder, MD, 2016

Conquer the World's Biggest Epidemics.
Join Us.

Investor confidence and invigorated leadership are combining to bring EndoBarrier to the US.

BBC News Item
EndoBarrier treatment for Obstructive Sleep Apnoea – 2nd ABCD EndoBarrier study

The Need by the Numbers

The Treatment Gap

Minimally Invasive Procedure Fills the “Treatment Gap”

  • Aids in the treatment of Type 2 Diabetes and Obesity
  • Minimal Risk
  • Cost-Effective

Videos

  • BBC News item

    EndoBarrier treatment for Obstructive Sleep Apnoea – 2nd ABCD EndoBarrier study
  • ABCD EndoBarrier Study

    1-year results, including 10-year CV Risk assessment – Robert Ryder, MD, 2016
  • Product Overview

    Pioneering treatment for diabetes & obesity
  • BBC News Item

    EndoBarrier treatment for diabetes & obesity following 1 year results of ABCD study

GID in the News

2/15

EndoBarrier® Study in Morbidly Obese Adolescents Completes Enrollment

First study of EndoBarrier in adolescents completed at University Children’s Hospital (UCH) in Ljubljana, Slovenia Preliminary data show BMI...
1/31

EndoBarrier® Receives German NUB Reimbursement Status 1 for Type 2 Diabetes and Obesity Therapy

FOR IMMEDIATE RELEASE BOSTON and SYDNEY — 1 February 2017 — GI Dynamics, Inc., (ASX:GID), a medical device company...
1/11

GI Dynamics, Inc. Provides 2017 Business Outlook and 2016 Review

BOSTON and SYDNEY — 11 January 2017 — GI Dynamics, Inc., (ASX:GID), a medical device company that has commercialized...
1/5

GI Dynamics, Inc. Appoints Oern R. Stuge, MD, MBA, Amid Change to Company’s Board of Directors

BOSTON and SYDNEY — 5 January 2017 — GI Dynamics, Inc. (ASX:GID), a medical device company that has developed an innovative...